DGAP-News: Heidelberg Pharma AG / Key word(s): Personnel 
Heidelberg Pharma Expands Management Team 
2021-03-01 / 07:22 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
PRESS RELEASE 
Heidelberg Pharma Expands Management Team 
- Dr. András Strassz promoted to Chief Medical Officer 
- Dr. Mathias Locher joins to fill newly created position of Chief Development Officer 
Ladenburg, Germany, 1 March 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced the appointment of Dr. András 
Strassz as Chief Medical Officer and Dr. Mathias Locher as Chief Development Officer. 
Dr. Strassz joined the company in April 2020 as Senior Medical Officer to build up the clinical development function. 
He has strong experience in clinical development, including in oncology. Dr. Strassz joined Heidelberg Pharma from 
Affimed, where he served as Medical Director. Previously, he held positions in clinical development at Sandoz and 
Amgen, among others. He holds both an MD and MBA from the University of Pécs, Hungary. 
Dr. Locher has over 30 years of experience in drug development. He joins Heidelberg Pharma from Janssen (Pharmaceutical 
Companies of Johnson & Johnson), where he was Senior Director - External Innovation at the J&J London Innovation 
Centre. Prior to that, he held management positions at Covagen, Merck Serono, Micromet (now part of Amgen) and ASTA 
Medica. Dr. Locher holds a PhD in biochemistry from the University of Tuebingen. 
Dr. Jan Schmidt-Brand, Chief Executive Officer and Chief Financial Officer of Heidelberg Pharma AG, commented: "I am 
very pleased that András Strassz and Mathias Locher are joining the Heidelberg Pharma management team. With our lead 
program, HDP-101, about to enter the clinic, we are evolving from a research organization to a clinical development 
company and with strengthening the team, we gain valuable know-how and necessary expertise. I look forward to working 
together with the growing team to achieve our goals." 
About Heidelberg Pharma 
Heidelberg Pharma is an oncology company and the first company to develop the toxin Amanitin into cancer therapies 
using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of 
action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop 
the Company's proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC 
candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. 
Heidelberg Pharma AG has entered into partnerships to further develop and commercialize its clinical assets upamostat 
(formerly MESUPRON^(R)) and TLX250-CDx (formerly REDECTANE^(R)). Heidelberg Pharma AG is listed on the Frankfurt Stock 
Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com. 
Contact                                        IR/PR support 
Heidelberg Pharma AG                           MC Services AG 
Corporate Communications                       Katja Arnold (CIRO) 
Sylvia Wimmer                                  Managing Director & Partner 
Tel.: +49 89 41 31 38-29                       Tel.: +49 89 210 228-40 
Email: investors[at]hdpharma.com               Cell: +49 (0)160 9360 3022 
Gregor-Mendel-Str. 22, 68526 Ladenburg         Email: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. -----------------------------------------------------------------------------------------------------------------------

2021-03-01 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de ----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      Heidelberg Pharma AG 
              Gregor-Mendel-Str. 22 
              68526 Ladenburg 
              Germany 
Phone:        +49 (0)89 41 31 38 - 0 
Fax:          +49 (0)89 41 31 38 - 99 
E-mail:       investors@hdpharma.com 
Internet:     www.heidelberg-pharma.com 
ISIN:         DE000A11QVV0 
WKN:          A11QVV 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1171818 
 
End of News   DGAP News Service 
=------------

1171818 2021-03-01

(END) Dow Jones Newswires

March 01, 2021 01:24 ET (06:24 GMT)